InMed Pharmaceuticals Investor Relations Material

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. It uses its drug development programs to treat diseases with high unmet medical need. The company's product pipelines include Epidermolysis Bullosa, Glucocerebrosidase Deficiency, Ocular Scarring, and Transdermal Cannabinoid delivery system. Its platform technology includes Biosynthesis process for natural plant-based cannabinoids, Bioinformatics databases to assess the pharmacological activity of existing and novel cannabinoids, and Drug delivery platforms that provide targeted therapeutic options. The company was formerly known as InMed BioPharma Inc. and changed its name to InMed Pharmaceuticals Inc. in December 2016. InMed Pharmaceuticals Inc. was founded in 2011 and is based in Vancouver, Canada.